The BioPharm Brief: AI, Immunology, and Regulatory Momentum

AstraZeneca reported consistent Phase III results for its IL-33 biologic in COPD, while Boehringer Ingelheim continues expanding its use of AI to accelerate drug discovery and disease research. Meanwhile, the U.S. Food and Drug Administration has accepted a biologics license application for Gazyva as a potential treatment for systemic lupus erythematosus, signaling progress in addressing unmet patient needs.